*Date and Time: 25/6/2021, 16:35 - 17:35 CEST
Global experience using PARP inhibitors in treatment of ovarian cancer
Which patient and disease factors influence the choice of PARP inhibitor and whether to use them in combination?
How do you approach the use of PARP inhibitors in practice?
How can we proactively manage PARP inhibitor–related adverse events to improve quality of life for patients?
Summary, Final Thoughts and Q&A
Jonathan Ledermann, MD, FRCP, FMed Sci
Professor of Medical Oncology
CRUK and UCL Cancer Trials Centre
UCL Cancer Institute
Honorary Consultant in Medical Oncology
London, United Kingdom
Frederik Marmé, MD PhD
Assistant Professor of Gynecology
Division of Gynecologic Oncology
Medical Faculty of Heidelberg
University of Heidelberg
Prof Isabelle Ray Coquard
Professor of Department of Medical Oncology
Clinical Science Institute of the Léon Bérard Center
The goal of this activity is to educate global gynecologic oncologists, medical oncologists, and other healthcare professionals about the recent developments in the use of PARP inhibitors in the treatment of ovarian cancer.
This educational program is intended for global gynecologic oncologists, medical oncologists, and other healthcare professionals who care for patients with ovarian cancer.
Upon completion of this activity, participants should be able to:
- Evaluate available long-term follow-up data from clinical trials investigating the use of PARP inhibitors in the management of ovarian cancer
- Apply new clinical findings in a clinical context and understand their therapeutic implications to optimize outcomes for patients with ovarian cancer
- Identify patients with ovarian cancer most likely to benefit from PARP inhibitor therapy as single agents or in combination
- Compare and contrast the toxicities associated with PARP inhibitors commonly used in therapy for ovarian cancer, and understand the available supportive management strategies
- Discuss with patients and colleagues ongoing clinical studies of PARP inhibitor–based treatment in ovarian cancer
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.